DRTS | Ticker Profile - Titan Protect

DRTS

Alpha Tau Medical Ltd.

Healthcare · Biotechnology · NCM

$9.35

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$929M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-21.46

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-90.5%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$14.50

+55% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 4 analysts covering this stock

About Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.

https://www.alphatau.com

Country: Israel Employees: 121 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

1.413

Excellent risk-adjusted returns

Kelly Fraction

0.0711

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

2.481

Returns exceed worst-case losses — strong risk profile

Annual Return

103.4%

Historical annualised return based on price data

Max Drawdown

-41.7%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.12

Moves slightly more than the broader market

52W High

$11.62

20% below the year high

52W Low

$2.81

233% above the year low

Avg Volume

507,932

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

2.4%

Low short interest — limited bearish positioning

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.66

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

20.68

Heavy leverage — higher financial risk if revenues decline

Current Ratio

7.79

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

7.31

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-56,875,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$17.00

Target Median

$14.50

Target Low

$8.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go